Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Aminoglycoside resistant enterococcal endocarditis

G M Eliopoulos1

  • 1Department of Medicine, Harvard Medical School, Boston, Massachusetts.

Infectious Disease Clinics of North America
|March 1, 1993
PubMed
Summary

Highly aminoglycoside-resistant enterococci are increasingly causing endocarditis. Alternative treatment strategies are necessary, focusing on cell wall-active agents for dual-resistant strains.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Daptomycin <i>In Vitro</i> Activity against Methicillin-Resistant Staphylococcus aureus Is Enhanced by d-Cycloserine in a Mechanism Associated with a Decrease in Cell Surface Charge.

Antimicrobial agents and chemotherapy·2013
Same author

Utility of peptide nucleic acid fluorescence in situ hybridization for rapid detection of Acinetobacter spp. and Pseudomonas aeruginosa.

Journal of clinical microbiology·2009
Same author

Antimicrobial agents for treatment of serious infections caused by resistant Staphylococcus aureus and enterococci.

European journal of clinical microbiology & infectious diseases : official publication of the European Society of Clinical Microbiology·2005
Same author

In vitro activity of an oral streptogramin antimicrobial, XRP2868, against gram-positive bacteria.

Antimicrobial agents and chemotherapy·2005
Same author

Safety and efficacy of glycopeptide antibiotics.

The Journal of antimicrobial chemotherapy·2005
Same author

In vitro activity of the new oxazolidinone AZD2563 against Enterococci.

Antimicrobial agents and chemotherapy·2002

Area of Science:

  • Infectious Diseases
  • Microbiology
  • Pharmacology

Background:

  • Infective endocarditis caused by highly aminoglycoside-resistant enterococci is uncommon but increasing.
  • High-level resistance to both streptomycin and gentamicin is becoming more prevalent in enterococcal strains.

Purpose of the Study:

  • To review current treatment strategies for enterococcal endocarditis.
  • To highlight the need for alternative therapies due to rising aminoglycoside resistance.
  • To guide clinical decision-making for managing infections caused by resistant enterococci.

Main Methods:

  • Literature review of existing studies and clinical case reports.
  • Analysis of antimicrobial resistance mechanisms and patterns in enterococci.
  • Evaluation of in vitro and animal model data for potential treatment regimens.

Main Results:

  • Screening for high-level streptomycin resistance is crucial for gentamicin-resistant isolates.
  • Synergistic killing may occur with cell wall-active agents and streptomycin for some strains.
  • For strains resistant to both aminoglycosides, cell wall-active agents alone may be effective, potentially curing 40-50% of cases.
  • Ampicillin is preferred for susceptible strains; vancomycin is an alternative for penicillin-intolerant or resistant cases.
  • Emerging resistance to glycopeptides and beta-lactams complicates treatment options.

Conclusions:

  • Urgent development of alternative treatment strategies for aminoglycoside-resistant enterococcal endocarditis is required.
  • Tailoring therapy based on specific resistance profiles is essential.
  • Further research is needed to validate novel treatment combinations and dosing regimens.

Related Experiment Videos